Crimson Wine Group LTD (CWGL) investors sentiment decreased to 0.57 in Q4 2017. It’s down -0.68, from 1.25 in 2017Q3. The ratio has worsened, as 4 funds started new and increased stock positions, while 7 decreased and sold their equity positions in Crimson Wine Group LTD. The funds in our database reported: 5.25 million shares, down from 5.28 million shares in 2017Q3. Also, the number of funds holding Crimson Wine Group LTD in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 4 Increased: 2 New Position: 2.
Analysts expect Trillium Therapeutics Inc. (NASDAQ:TRIL) to report $-0.62 EPS on May, 11.They anticipate $0.48 EPS change or 43.64% from last quarter’s $-1.1 EPS. After having $-0.72 EPS previously, Trillium Therapeutics Inc.’s analysts see -13.89% EPS growth. It closed at $6.05 lastly. It is down 12.70% since April 30, 2017 and is uptrending. It has outperformed by 1.15% the S&P500.
Since January 1, 0001, it had 12 insider buys, and 0 selling transactions for $159,441 activity.
The stock increased 1.53% or $0.14 during the last trading session, reaching $9.3. About 18,871 shares traded. Crimson Wine Group, Ltd. (CWGL) has 0.00% since April 30, 2017 and is . It has underperformed by 11.55% the S&P500.
Crimson Wine Group, Ltd., through its subsidiaries, engages in the production and sale of ultra-premium and wines. The company has market cap of $223.18 million. The firm operates through two divisions, Wholesale and Direct to Consumer. It has a 36.05 P/E ratio. The firm sells wines through independent wine and spirit distributors in the United States; and independent importers and brokers internationally.
Price Michael F holds 1.29% of its portfolio in Crimson Wine Group, Ltd. for 969,200 shares. Lawson Kroeker Investment Management Inc Ne owns 360,955 shares or 1.24% of their US portfolio. Moreover, Beck Mack & Oliver Llc has 1.11% invested in the company for 3.16 million shares. The New York-based Mutual Of America Capital Management Llc has invested 0.11% in the stock. Menlo Advisors Llc, a California-based fund reported 12,203 shares.
Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company has market cap of $80.63 million. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. It currently has negative earnings. The Company’s product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase.